孟鲁司特钠联合布地奈德雾化吸入对肺炎支原体肺炎患儿血清炎症介质水平的影响

Effects of Montelukast Sodium Combined with Budesonide Aerosol Inhalation on Serum Levels of Inflammatory Mediators in Children with Mycoplasma Pneumoniae Pneumonia

目的探讨孟鲁司特钠联合布地奈德雾化吸入对肺炎支原体肺炎(MPP)患儿血清炎症介质水平的影响。方法选取2018年3月至2019年3月沈阳市儿童医院收治的MPP患儿112例,将其应用随机数字表法分为两组,每组56例。对照组接受布地奈德治疗,观察组则加用孟鲁司特钠治疗。比较两组临床疗效、炎症介质水平[肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)、C反应蛋白(CRP)]及不良反应。结果观察组治疗有效率(92.86%)高于对照组(78.57%),差异有统计学意义(P<0.05);治疗前两组TNF-α、IL-8、CRP水平比较,差异无统计学意义(P>0.05);治疗后观察组TNF-α(8.76±4.68)pg/ml、IL-8(10.41±4.90)pg/ml、CRP(5.26±2.14)mg/L,低于对照组的(16.59±4.20)pg/ml、(19.74±5.28)pg/ml、(8.97±2.48)mg/L低,差异有统计学意义(P<0.05);不良反应发生率观察组(10.71%)、对照组(5.36%),两组比较,差异无统计学意义(P>0.05)。结论 MPP患儿接受孟鲁司特钠、布地奈德雾化吸入联合治疗有利于下调炎症介质水平,提升MPP治疗效果,且未明显增加不良反应。

Objective To explore the effects of montelukast sodium combined with Budesonide aerosol inhalation on serum levels of inflammatory mediators in children with mycoplasma pneumonia(MPP).Methods A total of 112 children with MPP who were treated from March 2018 to March 2019 in Shenyang Children’s Hospital,were selected.The patients were divided into 2 groups by random number table,with 56 cases in each group.The control group received budesonide and the observation group received montelukast sodium.The clinical efficacy and inflammatory factor levels[TNF-α,IL-8,C-reactive protein(CRP)]and adverse reactions were observed.Results The total effective rate of the observation group(92.86%)was higher than that of the control group(78.57%),and the difference was statistically significant(P<0.05).There was no statistically significant difference in the levels of TNF-α,IL-8 and CRP between the 2 groups before treatment.After treatment,TNF-α(8.76±4.68)pg/mL,IL-8(10.41±4.90)pg/mL,CRP(5.26±2.14)mg/L were observed,which was lower than that of the control group.(16.59±4.20)pg/mL,(19.74±5.28)pg/mL,(8.97±2.48)mg/L,the difference was statistically significant(P<0.05);The difference in incidence of adverse reactions between the observation group(10.71%)and control group(5.36%)was not statistically significant(P>0.05).Conclusion Inhalation combined with montelukast sodium and budesonide in children patients with MPP is beneficial to down-regulate the level of inflammatory factors and improve the therapeutic effects of MPP without significantly increasing the adverse reactions.